The regulation and remodeling of the tumor microenvironment (TME) are closely associated with how cancers typically progress ...

Rechallenging patients with ICIs may not be beneficial in advanced RCC, but Tivozanib monotherapy shows promise as an ...

FDA also approved the Ventana CLDN18 (43-14A) RxDx Assay, from Ventana Medical Systems, Inc. and Roche Diagnostics, to ...

The following is a summary of “Association of mutation profiles with metastasis in patients with non-small cell lung cancer,” ...

Adding immunotherapy to platinum-gemcitabine chemotherapy can improve outcomes in patients with advanced urothelial carcinoma, but that may depend on the platinum agent used, data suggest.

It may soon be possible to determine which patients with a type of liver cancer called hepatocellular carcinoma would benefit ...

According to a preclinical study conducted by Weill Cornell Medicine researchers, it may soon be feasible to detect whether ...

What’s more, AM-101 improved radiation treatment, slowing down the growth of NSCLC subcutaneous xenograft tumors in mice, by ...

Astellas Pharma Inc. (ALPMY, ALPMY) said that the U.S. Food and Drug Administration has approved VYLOY (zolbetuximab-clzb) in ...

Combined company will operate as TuHURA Biosciences, Inc. and advance pipeline of novel technologies to overcome resistance to cancer immunotherapy ...

Exelixis is advancing its pipeline with zanalintinib and XB010, exploring new avenues in oncology beyond its cabozantinib ...

Under the agreement, Roche will supply atezolizumab globally and Tempest will sponsor and lead the pivotal study. This agreement builds on a clinical collaboration between the companies pursuant to ...